A Study of Mycophenolate Mofetil and Cyclosporin, Without Concomitant Corticosteroids, After a First Renal Transplant
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The trial is planned as a multicentric, randomized, prospective, open study in accordance with a 1/1 plan, on parallel groups and 2 arms of treatment. A total of 200 patients with chronic renal insufficiency, included in the French national waiting list of the Establishment Français des Greffes [French Transplants Institution] and receiving a first renal transplant will be included, after signed agreement, in this study. All the patients will receive organs taken from brain-dead subjects. The patients will be given immunosuppressant treatment based on rabbit anti-T lymphocyte serum, CellCeptÒ and NeoralÒ cyclosporin. One group of 100 randomised patients will be given standard corticosteroid therapy as well during the first six months following the transplant. This group will be compared with a second group of 100 randomised patients who will be given a single dose of corticosteroids. The main aim of this study is to evaluate the number of acute rejection episodes in patients given a first renal transplant and subjected to an immunosuppressant protocol not containing corticosteroids. The hypothesis which is proposed is that, in the absence of corticosteroids and/or calcineurin inhibitors (i.e. cyclosporin and tacrolimus), antilymphocyte serum results in a certain state of "tolerance" in respect of the allograft. The second objective concerns the beneficial effect which the absence of corticosteroids may have on short- and long-term postoperative morbidity and mortality. One may in fact assume that the absence of corticosteroids will result in an extension of the transplant patient's life expectancy as a result of the reduction in cardiovascular complications. Cardiovascular complications are the most frequent cause of death after a renal transplant.
Condition or disease
Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.Drug: Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.
A Prospective, Randomized, Open, Multicentric Study Intended to Evaluate the Efficacy and Tolerability of Sequential Treatment Based on Rabbit Anti-T-lymphocyte Serum, of Mycophenolate Mofetil and of Cyclosporin, Without Concomitant Corticosteroids, After a First Cadaveric Renal Transplant
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
To evaluate the number of acute rejection episodes during the first year after transplantation in patients given a first renal transplant and subjected to an immunosuppressant protocol not containing corticosteroids.
Secondary Outcome Measures
Clinical tolerance of the treatment with antilymphocyte
Any complication related to the corticosteroid treatment
Graft survival at 1, 2, 3, 4 and 5 years
Patient survival at 1, 2, 3, 4 and 5 years
Incidence of infectious and tumoral complications at 1, 2, 3, 4 and 5 years
Incidence of cardiovascular complications at 1, 2, 3, 4 and 5 years
Incidence of metabolic and lipid disorders at 1, 2, 3, 4 and 5 years
Bone osteodensitometry and folic acid levels before transplantation and at 2 weeks, 3 and 6 month after transplantation; then yearly up to 5 years.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient who is a candidate for a first cadaver renal transplantation and included on the national list of the Etablissement Français des Greffes
Man or woman aged between 18 and 65 years
Women of reproductive age must agree to use a reliable contraceptive method throughout the first year of the study
Donor aged between 18 and 65 years
Patient who has been given full information about the study and who has given his written informed consent to take part in it.
Women who are pregnant or breast-feeding
Patient with an immunological risk considered high and defined as a percentage of anti-HLA antibodies of ³20% (previous or recent determination of T lymphocytes)
Patient with a history of allergy to rabbit proteins
Cold ischaemia time of more than 36 hours
Patient allergic to macrolide antibiotics, to tacrolimus or to MMF
Patient on immunosuppressant treatment before transplantation
Patient suffering from a malignant neoplasm or with a history of malignant neoplasia, with the exception of treated baso- or spinocellular cancers
Patient waiting for another transplant in addition to the kidney
Patient who has already received an organ or tissue graft